Palabras clave
Cómo citar
Resumen
Introducción: El lupus eritematoso sistémico (LES) es una enfermedad autoinmune crónica que presenta diversas manifestaciones clínicas. Existe un interés creciente en la exploración de nuevos biomarcadores para utilizarlos como indicadores de actividad de la enfermedad y/o predecir los brotes de la enfermedad. Las investigaciones sobre metaloproteinasas en LES no son consistentes y a veces se contradicen. Objetivos: El objetivo de este estudio fue evaluar el nivel sérico de metaloproteinasa-3 (MMP-3) en pacientes con LES y su relación con la actividad clínica de la enfermedad y otros biomarcadores de actividad utilizados en la práctica diaria. Materiales y Métodos: Se estudiaron 47 pacientes con LES. La actividad de la enfermedad individual se cuantificó utilizando la puntuación del índice de actividad de la enfermedad (SLEDAI). Se incluyeron veinticinco voluntarios sanos como controles. Resultados: Los niveles séricos de MMP-3 en los pacientes con LES fueron significativamente más altos que los de los controles (120 ± 75 ng / ml frente a 13,5 ± 6,5 ng / ml p˂0,001); conuna correlación positiva (R = 0,778) entre los niveles séricos de la MMP-3 y la puntuación SLEDAI y CIC-C3b (R = 0,486). Conclusiones: La correlación entre los niveles séricos de MMP-3 y la actividad de la enfermedad en pacientes con LES sugieren que las MMP-3 pueden estar involucrada en el proceso inflamatorio del LES.
Referencias
Wallace DJ, Hahn BH. eds. Dubois’ lupus erythematosus. Philadelphia: Williams and Wilkins, 1993:69-76.
Winchester RJ. Systemic lupus erythematosus pathogenesis. In: Koopman WJ. eds. Arthritis and Allied Conditions. Birmingham Alabama: William and Wilkins, 1996: 1361-91.
Dean GS, Tyrrell-Price J, Crawley E et al. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000; 59:243-51.
Segal R, Bermas BL, Dayan M et al. Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helpercell 1/T helper cell 2-type cytokines in disease. J Immunol 1997; 158:3009-16.
Theofilopoulos AN, Lawson BR. Tumor necrosis factor and other cytokines in murine lupus. Ann Rheum Dis 1999; 58 (Suppl.):149-55.
Eilat E, Dayan M, Zinger H et al. The mechanism by which a peptide based on the complementarity determining region-1 of a pathogenic anti-DNA autoantibody ameliorates experimental SLE. Proc Natl Acad Sci 2001; 98:1148-53.
MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinase-1 in rheumatoid synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem 1990; 265(28):P17238-45.
Zhang Y, McCluskey K, Fujii K, Wahl LM. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-a, granulocyte-macrophage CSF, and IL-1b through prostaglandin -dependent and -independent mechanisms. J Immunol 1998; 161(6): 3071-6.
Fredrik R, Geir H, Nils E. Gilhus: serum levels of matrix metalloproteinases: implications in clinical neurology. Eur Neurol 2012; 67:121-28
Malemud CJ. Matrix metalloproteinases and synovial joint pathology. Prog Mol Biol Transl Sci 2017; 148:305-325.
DeLeon-Pennell KY, Meschiari CA, Lindsey ML. Matrix metalloproteinases in myocardial infarction and heart failure. Prog Mol Biol Transl Sci 2017; 147:75-100
Shingleton WD, Hodges DJ, Brick P, Cawston TE. Collagenases: A key enzyme in collagen turnover. Biochem. Cell. Biol. 1996; 74, 759-775. 13. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J. Immunol. 1996;156, 1-4.
Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: structures, evolution and diversification. FASEB. J. 1998;12,1075-1095.
Ozenci V, Rinaldi L, Teleshova N, Matusevicius D, Kivisak P, Kouwenhoven M et al. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J. Autoimmun. 1999; 12(4), 297-303.
Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J. Clin. Invest. 1994; 94(6), 2177-2189.
Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP- 1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J. Rheumatol. 1999;26, 251-258.
Creange A, Sharshar T, Planchenault T, Christov C, Poron F, Raphael JC et al. Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barre syndrome. Neurology 1999; 53:1683-1691.
Liu Z, Shipley JM, Vu TH, Zhou X, Diaz LA, Werb Z et al. Gelatinase B-deficient mice are resistant to experimental bullous Pemphigoid. J. Exp. Med. 1998;188, 475-482.
Hughes PM, Wells GMA, Clements JM, Gearing AJ, Redford EJ, Davies M et al. Matrix metalloproteinase expression during experimental neuritis. Brain 1998;121, 481-494.
Ichikawa, Y., Yamada, C., Horiki, T., Hoshina, Y., and Uchiyama, M., Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis. Clin. Exp. Rheumatol. 1998; 16, 533-540.
Zucker S, Increased serum stromelysin-1 levels in systemic lupus erythematosus: Lack of correlation with disease activity. J. Rheumatol. 1999;26, 78-80.
Závada J, Uher M, Svobodová R, Olejárová M, Hušáková M, Ciferská H et al. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy. Arthritis Res Ther 2015; 17:341.
Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 2003; 62(5):435-9.
Kim KJ, Kim JY, Baek IW, Kim WU, and Cho CS. Elevated Serum Levelsof Syndecan1 Are Associated with Renal Involvement in Patients with Systemic Lupus Erythematosus. J Rheumatol 2015; 42 (2), 202-9.
Aringer M et al. 2019 European League Against Rheumatism /American College of Rheumatology classification criteria for systemislupus erythematosus. Ann Rheum Dis. 2019; 78:1151-59 y Arthritis Rheumatol. 2019; 71:1400-12.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A Disease Activity Index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
Minowa K, Amano H, Nakano S, Ando S, Watanabe T, Nakiri Y, Amano E, Tokano Y, Morimoto S, Takasaki Y. Elevated serum level of circulating syndecan-1 (CD138) in active systemic lupus erythematosus. Autoimmunity 2011; 44:357-62.
Fajardo-Robledo NS, Diaz-Rizo V, Rocha-Muñoz A, Muñoz-Valle J, Gonzalez-Lopez L and Gamez-Nava J. Serum levels of syndecan-1 and organ involvement in systemic lupus erythematosus. Ann Rheum Dis 2014; 73(2): 831-2.
Baek IW, Kim KJ, Kim JY, Park SJ, Yoon C, Kim WU, Cho CS. Serum Level of Syndecan-1 Is Associated with Disease Activity in Patients with Systemic Lupus Erythematosus. Arthritis Rheum 2012; 64(10): 613
Sekita K, Doi T, Muso Eri T, Yoshida H, Kanatsu K, Hamashima Y. Correlation of C3b fixing circulating immune complexes with diseaseactivity and clinical parameters in patients with systemic lupus erythematosus. Clin. exp. Immunol. 1984; 55, 487-494.
Mannello F, Tonti GA, Bagnara GP, Papa S. Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. Stem Cells 2006; 24:475–81.
Gaipl US, Voll RE, Sheriff A, Franz S, Kalden JR, Herrmann M: Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev. 2005, 4: 189-194.
Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR: Role of apoptosis in autoimmunity. Apoptosis. 2000, 5: 443-449.